Business Wire

ONWARD Awarded Nine New Patents in Collaboration with Caltech, UCLA, EPFL, and University of Louisville

Share

ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury, today announces the company and its partners have been awarded nine new patents, seven of them in collaboration with leading neuroscience research laboratories at Caltech, UCLA, EPFL, and University of Louisville.

The patents cover a broad range of technologies and activities encompassing ONWARD’s implantable and external technology platforms, ARCIM and ARCEX, and protecting key elements of those systems such as lead designs, spinal cord stimulation paradigms, closed-loop control systems and machine learning algorithms. The patents were awarded in the US, France, Canada, and Germany.

“Our many exclusive IP license agreements with the world’s top neuroscience research universities continue to bear fruit, adding to an already impressive IP portfolio of over 300 issued or pending patents”, said Dave Marver, Chief Executive Officer of ONWARD. “We are taking full advantage of our first-mover position to secure seminal and strategic intellectual property borne from our own engineering labs or prosecuted in collaboration with others.”

The Company has IP licensing arrangements in place with Caltech, EPFL, UCLA, University of Louisville, University of Minnesota, Univesity of British Columbia and University of Calgary.

To learn more about ONWARD’s ARC Therapy and the company’s vision to restore movement, independence and health in people with spinal cord injury, please visit ONWD.com.

About ONWARD

ONWARD is a medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury. ONWARD’s work builds on more than a decade of basic science and preclinical research conducted at the world’s leading neuroscience laboratories. ONWARD’s ARC Therapy, which can be delivered by implantable (ARCIM) or external (ARCEX) systems, is designed to deliver targeted, programmed stimulation of the spinal cord to restore movement and other functions in people with spinal cord injury, ultimately improving their quality of life. ONWARD has received three Breakthrough Device Designations from the FDA encompassing both ARCIM and ARCEX. The company’s first FDA pivotal trial, called Up-LIFT, completed enrollment in December 2021 with 65 subjects worldwide.

ONWARD is headquartered at the High Tech Campus in Eindhoven, the Netherlands. It maintains an office at the EPFL Innovation Park in Lausanne, Switzerland and has a growing U.S. presence in Boston, Massachusetts, USA. For additional information about the company, please visit ONWD.com.

Disclaimer

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors’ current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For Company Enquiries:

ONWARD
info@onwd.com
For Media and Investor Enquiries:

Backstage Communication
Gunther De Backer
Tel: +32 (0)475 903 909
gunther@backstagecom.be

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

H.I.G. Infrastructure to Acquire EYSA24.1.2022 12:30:00 EET | Press release

H.I.G. Capital (“H.I.G.”), a leading global alternative investment firm with more than $47 billion of equity capital under management, announced that an affiliate has signed a definitive agreement to acquire EYSA Group (“EYSA” or the “Company”), a market leading provider of smart mobility solutions. The transaction is subject to regulatory approvals. The transaction is led by the H.I.G. Infrastructure Partners fund. Terms were not disclosed. EYSA is headquartered in Madrid, Spain, with an international presence in the USA, Mexico, Colombia, Ecuador and Brazil. Leveraging on “ParkXplorer”, its proprietary IT platform, the Company has become a one-stop-shop for more than 100 cities across Spain, Latin America and the USA. EYSA has long term relationships with municipalities and private clients who desire comprehensive, automated solution integrating all their mobility needs. Over the past several years, EYSA has evolved from a purely regulated parking operator, to an integrated tech-enab

European Manufacturers Embrace the Cloud to Improve Their Agility24.1.2022 12:00:00 EET | Press release

European manufacturing firms are embracing cloud-based technologies and services to accelerate their go-to-market plans and improve digital marketing efforts, according to a new report published today by Information Services Group (ISG) (Nasdaq: III), a leading global technology research and advisory firm. The 2021 ISG Provider Lens™ Manufacturing Industry Services Report for Europe finds manufacturers on the continent also looking to the cloud to enable direct-to-consumer business models. “Manufacturers in Europe are turning to the cloud to increase their business agility,” said Christian Decker, EMEA partner, ISG Smart Manufacturing. “And they are turning to manufacturing services providers to help them create new reference architectures and bring resiliency to their operations.” In addition, manufacturing firms want service providers to help them establish robust configuration management databases and leverage automated testing, including shift-left techniques, the report says. The

Zyxel Communications to Join Open Networking Foundation Aligning With Projects Focused on Broadband Transformation24.1.2022 10:00:00 EET | Press release

Zyxel Communications now is a member of the Open Networking Foundation (ONF), a non-profit operator-led consortium driving transformation of access and edge network infrastructure. Zyxel will join two of the foundation’s ongoing projects: VOLTHA and SEBA. VOLTHA is an open-source project creating a hardware abstraction for broadband access equipment. It supports the principle of multi-vendor, disaggregated, “any broadband access a service” for the central office. VOLTHA is an access network component of SEBA – a lightweight platform based on a variant of R-CORD. SEBA supports a multitude of virtualized access technologies at the edge of the carrier network, including PON and G.Fast. Through its ONF membership, Zyxel will help bring state of the art white-box hardware to other community members and share expertise in manufacturing and production, driving community cooperation, and delivering easy-to-deploy hardware and software solutions to the world’s service providers. “By bringing Zy

Health Canada Approves Ipsen’s Sohonos™ (palovarotene capsules) as the First Approved Treatment for Fibrodysplasia Ossificans Progressiva24.1.2022 09:00:00 EET | Press release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the Health Canada approval of Sohonos (palovarotene capsules), an oral selective retinoic-acid receptor gamma (RARγ) agonist indicated to reduce the formation of heterotopic ossification (HO; new bone formation) in adults and children aged 8 years and above for females and 10 years and above for males with fibrodysplasia ossificans progressiva (FOP).1 Sohonos is approved for the treatment of patients with FOP for both chronic use, and for flare-ups, in these patient populations. This decision marks the first approval for Sohonos worldwide. Dr. Howard Mayer, Executive Vice President and Head of Research and Development, Ipsen, said “FOP is a progressive and debilitating condition which has such a profound impact on patients, and their families. Until today, there was no approved medicine, and we are proud to bring this important new medicine to the FOP community.” FOP is characterized by new bone formation outside of the

Altasciences Chosen by Virpax Pharmaceuticals, Inc. to Conduct First-in-Human Study of Epoladerm™ for Chronic Pain Associated with Osteoarthritis of the Knee21.1.2022 19:00:00 EET | Press release

Altasciences is pleased to have been chosen by Virpax® Pharmaceuticals, Inc. (“Virpax”) (NASDAQ:VRPX) to conduct a first-in-human study of Epoladerm™ (diclofenac epolamine) for chronic pain associated with osteoarthritis of the knee. This treatment is supplied in a pre-filled device for administration as a topical spray film. The study will be conducted in Q2 2022 at Altasciences’ clinical pharmacology unit in Montreal, Canada. “We look forward to working with Altasciences to accelerate the development of this analgesic treatment and provide robust data in support of the 505(b)(2) FDA approval pathway,” stated Virpax’s Chairman & CEO, Anthony P. Mack. Virpax’s proprietary technology provides a pre-filled canister for the therapeutic application of a clear, fast-drying spray film that is thinner than a standard liquid bandage. This technology offers convenience and eliminates the need for messy creams or gels. Altasciences leverages decades of experience conducting first-in-human clinic

OMRON Healthcare Remote Patient Monitoring Services Win “Best of” Honors at CES 202221.1.2022 18:21:00 EET | Press release

OMRON Healthcare, Inc., the global leader in remote blood pressure monitoring and personal health technology, spotlighted its new remote patient monitoring services at the 2022 Consumer Electronics Show (CES) and won “Best of” honors for its offerings in the U.K. and U.S: Hypertension Plus by OMRON in the U.K. was selected as a TWICE Picks Awards winner for the 2022 TWICE, Residential Systems and TechRadar Pro Picks Awards VitalSight™ by OMRON in the U.S. was recognised as an INSIDER “Best of” CES selection These remote patient monitoring services gained recognition at the world’s largest innovation show as breakthrough health technology designed to foster greater active health condition management, strengthen the patient-physician connection, and guide behavior change to reduce health risks, while advancing the company’s mission of Going for Zero heart attacks and strokes. “OMRON developed Hypertension Plus as the first step toward transforming chronic care in the U.K., while VitalSig

Schlumberger Announces Fourth-Quarter and Full-Year 2021 Results21.1.2022 14:50:00 EET | Press release

Schlumberger Limited (NYSE: SLB) today reported results for the fourth-quarter and full-year 2021. Fourth-Quarter Results (Stated in millions, except per share amounts) Three Months Ended Change Dec. 31, 2021 Sept. 30, 2021 Dec. 31, 2020 Sequential Year-on-year Revenue* $6,225 $5,847 $5,532 6% 13% Income before taxes - GAAP basis $755 $691 $471 9% 60% Net income - GAAP basis $601 $550 $374 9% 61% Diluted EPS - GAAP basis $0.42 $0.39 $0.27 8% 56% Adjusted EBITDA** $1,381 $1,296 $1,112 7% 24% Adjusted EBITDA margin** 22.2% 22.2% 20.1% 2 bps 208 bps Pretax segment operating income** $986 $908 $654 9% 51% Pretax segment operating margin** 15.8% 15.5% 11.8% 31 bps 401 bps Net income, excluding charges & credits** $587 $514 $309 14% 90% Diluted EPS, excluding charges & credits** $0.41 $0.36 $0.22 14% 86% Revenue by Geography International $4,898 $4,675 $4,343 5% 13% North America* 1,281 1,129 1,167 13% 10% Other 46 43 22 n/m n/m $6,225 $5,847 $5,532 6% 13% *Schlumberger divested certain busi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom